The goal of the proposed study is to evaluate the efficacy and safety of tolcapone in
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT00927563
Ages eligible for Study
21 Years to 75 Years
Genders eligible for Study
Accepts Healthy Volunteers
Men and women age 21-75;
Meet diagnostic criteria for current pathological gambling based on DSM-IV criteria and confirmed using the clinician-administered Structured Clinical Interview for Pathological Gambling (SCI-PG) (Grant et al., 2004);
Gambling behavior within 2 weeks prior to enrollment;
Women of child bearing age are required to have a negative result on a beta-human chorionic gonadotropin pregnancy test;
Women of childbearing potential utilizing a medically accepted form of contraception defined as double barrier, oral contraceptive, injectable contraceptive, implantable contraceptive devices, and abstinence.
Infrequent gambling (i.e. less than one time per week) that does not meet DSM-IV criteria for PG;
Unstable medical illness or clinically significant abnormalities on laboratory tests, EKG, or physical examination at screen as determined by the investigator;
History of elevated liver enzymes (AST/ALT) or other liver abnormalities;
History of seizures;
Myocardial infarction within 6 months;
Current pregnancy or lactation, or inadequate contraception in women of childbearing potential;
A need for medication other than tolcapone with possible psychotropic effects or unfavorable interactions as determined by the investigator;
Clinically significant suicidality (defined as score 2 or higher on HAM-D item 3);
Current co-morbid Axis I disorder determined by the Structured Clinical Interview for DSM-IV (SCID), (First et al., 1995) - except for nicotine dependence;
Lifetime history of bipolar disorder type I or II, schizophrenia, or any psychotic disorder determined by SCID;
Clinically significant cognitive impairment (defined as score less than 88 on 3MS);
Current or recent (past 3 months) DSM-IV substance abuse or dependence;
Positive urine drug screen at screening;
Initiation of psychotherapy or behavior therapy for pathological gambling within 3 months prior to study baseline;
Previous treatment with tolcapone;
Treatment with an investigational medication or depot neuroleptics within 3 months;
Refusal to sign the tolcapone information sheet.
All locations for NCT00927563
United States (1)
Ambulatory Research Center
Minneapolis, Minnesota, United States, 55454
Trial results for NCT00927563
Participant Flow: Overall Study
22 / 24
Completed / Started
Serious Adverse Events
0 / 24
Affected / At Risk
Other Adverse Events
10 / 24
Affected / At Risk
View full eligibility
Tris trial is registered with FDA with number: NCT00927563. The sponsor of the trial is University of Chicago and it is looking for 24 volunteers for the current phase.
Official trial title: Tolcapone Treatment of Pathological Gambling: An Open-Label Study
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Thank you for applying!
We'll contact you soon with more information.
FindMeCure is constantly improving its search. Take part in it and help millions by filling our patients' survey!